MAPT and Alzheimer disease: The inclusion criteria comprised patients between the age of 60 to 85 years with early symptomatic AD with gradual and progressive change in memory function for ≥6 months—this was defined as prodromal AD or mild AD with dementia, MMSE scores between 20 and 28, intermediate tau levels with 18F-flortaucipir PET tau SUVR between 1.10 and 1.46, and patients with topographically advanced AD despite an SUVR < 1.10, and elevated amyloid levels ≥ 37 CL.